Array BioPharma, Inc. to Present Clinical Data on ARRY-520, a KSP Inhibitor, and ARRY-614, a Dual p38/Tie2 Inhibitor, at the 2011 American Society of Hematology Annual Meeting

BOULDER, Colo.--(BUSINESS WIRE)--Array BioPharma Inc. (NASDAQ: ARRY) today announced data will be presented on two drug candidates, ARRY-520, a KSP inhibitor, and ARRY-614, a dual p38/Tie2 inhibitor, at the 2011 Annual Meeting of the American Society of Hematology in San Diego, California.